ESG

A familiar quit-smoking app has been rebuilt into a powerful research tool, powering Australia's largest cessation trial and setting a new standard.

IO Biotech’s cancer vaccine posts impressive 5-year survival data, but a narrow miss in its pivotal trial creates an uncertain path in a competitive market.

Beijing touts its Sanjiangyuan project as a win for ecology and herders. But beyond the state narrative lies a complex story of coercion and cultural risk.

New rankings name Germany's top cancer hospitals, but the real story is the rise of platforms shaping a multi-billion dollar global health market.

CMS's new ACCESS model spotlights virtual care, positioning firms like FlyteHealth to lead a tech-driven transformation in managing chronic illness.

How a Defense Logistics Agency grant to 6K Energy for advanced cathode tech aims to sever risky foreign supply chains and secure America's defense.

A new partnership claims to power an AI with meditated 'love' from at-risk communities. Is this a bold new paradigm or a controversial social experiment?

SEG Solar's $80M Indonesian plant isn't just a new factory; it's a strategic move to build a non-FEOC solar supply chain for the United States.

Huntington Bank appoints veteran strategist Marc Dizard as CIO, signaling a major push to modernize its investment platform and challenge regional rivals.

A sustainable energy firm's bold move into digital assets signals a new era of institutional crypto adoption, driven by South Korean demand for Ripple.

Anixa Biosciences now fully controls its breast cancer vaccine after promising Phase 1 data. What does this strategic move mean for investors and medicine?

Odysight.ai's new sensors offer a live video feed from inside hot, oil-filled machinery, a breakthrough poised to transform industrial predictive maintenance.

A Minneapolis firm is testing a graft that helps the body rebuild its own arteries. This could end a painful, risky part of traditional heart bypass surgery.

With three major awards, NanaWall's new glass system reveals how deep engineering and market foresight are reshaping the value of architectural components.

An Indiana biotech prepares for biotech's biggest stage, showcasing a pipeline that offers new hope for chronic endocrine and metabolic disorders.

This new partnership is more than a sponsorship. It's a strategic move to close the gender data gap in sports science and redefine athlete care for women.

Quince Therapeutics' Phase 3 trial completion for Ataxia-Telangiectasia offers hope, but the real story is its innovative red blood cell drug delivery platform.

A junior miner begins a high-stakes drill program in Arizona, betting on advanced geology to find the copper essential for the world's energy transition.

Vanda Pharmaceuticals submits its novel GPP therapy, imsidolimab, for FDA review, offering new hope for patients and bolstering its rare disease portfolio.

A landmark green ammonia project in Spain offers a blueprint for industrial decarbonization, holding key strategic lessons for the biopharmaceutical sector.